levofloxacin has been researched along with Community Acquired Infection in 175 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (4.57) | 18.2507 |
| 2000's | 107 (61.14) | 29.6817 |
| 2010's | 57 (32.57) | 24.3611 |
| 2020's | 3 (1.71) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, CL; Jeong, J; Jeong, SH; Jung, HJ; Kim, HR; Kim, S; Lee, EY; Lee, JN; Shin, JH | 1 |
| Cosler, L; Gupta, R; Kwa, A; Lodise, TP; Smith, RP | 1 |
| Brown, SD; Critchley, IA; Janjic, N; Tillotson, GS; Traczewski, MM | 1 |
| Chiba, N; Hasegawa, K; Iwata, S; Matsubara, K; Morozumi, M; Nakayama, E; Sunakawa, K; Takayanagi, R; Ubukata, K | 1 |
| Fritsche, TR; Jones, RN; Sader, HS | 2 |
| Danese, P; DeVito, J; Franceschi, F; Lawrence, L; Sutcliffe, J | 1 |
| Laohavaleeson, S; Nicolau, DP; Tessier, PR | 1 |
| Chi, Z; Pan, X; Tang, W; Yin, Y; Zhao, M | 1 |
| Cheong, HJ; Hyun, H; Kim, WJ; Noh, JY; Seong, H; Song, JY; Yoon, JG | 1 |
| Hong, MY; Hsieh, CC; Ko, WC; Lee, CC; Lee, CH; Tang, HJ; Yang, CY | 1 |
| Abushanab, L; Alshamayleh, N; Anzueto, A; Arabiat, H; Diab, A; Haddad, G; Jaber, W; Khalil, B; Kufoof, N; Momani, D; Mughrabi, M; Mulhem, A; Obaidat, M; Odat, E; Ramadan, M; Wadi Al Ramahi, J; Zahran, A | 1 |
| Chen, L; Du, X; Han, Y; Jian, Y; Xuan, J | 1 |
| Cardoso, L; Gonçalves, JR; Marques, R; Serra, P | 1 |
| Chang, CM; Hong, MY; Hung, YP; Ko, WC; Lee, CC; Lee, CH; Wang, JL | 1 |
| Huang, Y; Jiao, Y; Jin, SY; Li, YS; Metersky, ML; Nie, XM; Wang, H; Yang, ZW | 1 |
| Cho, SY; Chung, DR; Ha, YE; Huh, K; Kang, CI; Peck, KR; Seok, H | 1 |
| Rech, MA; Steuber, H; Williams, D | 1 |
| Bulkow, L; Gordon, K; Stevens, R; Westley, B | 1 |
| Kazi, S; Preston, GC | 1 |
| Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D | 1 |
| Dadras, O; Dadsetan, B; Heidari, H; Izadi, M; Jafari, S; Mazaheri, E; Najafi, Z; SeyedAlinaghi, S; Voltarelli, F | 1 |
| Chang, LW; Chang, YT; Cheng, SL; Chuang, YC; Hsu, MC; Perng, WC; Tsao, SM; Wu, RG | 1 |
| Atic, A; Basic-Jukic, N; Kirincich, J; Sakic, Z | 1 |
| Hatakeyama, S; Matsui, H; Morisawa, Y; Sasabuchi, Y; Sasahara, T; Suzuki, J; Yamada, T; Yasunaga, H | 1 |
| Clark, K; Craft, JC; Das, A; Fernandes, P; Jamieson, BD; Oldach, D; Schranz, J; Scott, D | 1 |
| Chung, DR; Hsueh, PR; Kang, CI; Kim, SH; Peck, KR; So, TM; Song, JH | 1 |
| Kalugin, VV; Kondrat'eva, TV; Makarevich, AM; Zaĭtsev, AA | 1 |
| Li, F; Liu, Y; Pu, C; Ren, X; Ren, Y; Sui, DJ; Sun, L; Sun, T; Wang, R; Yang, Z | 1 |
| Daryanani-Daryanani, R; Estevez-Dominguez, R; Gil-Diaz, A; Gil-Reyes, J; Monzon-Moreno, C | 1 |
| Huang, JA; Lv, XJ; Si, B; Sun, SH; Wang, C; Wu, JF; Xiao, ZK; Xie, CM; Xiu, QY; Zhang, DP; Zhang, YY; Zhao, X | 1 |
| Duncan, R; Gilman, M; Gray, A; James, N | 1 |
| Chen, YH; Hsueh, PR; Huang, CH; Lai, CC | 1 |
| Chang, FY; Chiu, CH; Lin, DY; Lin, HA; Lin, HC; Lin, JC; Wang, JX; Yang, YS; Yeh, KM | 1 |
| Cao, B; Chen, R; Du, Y; Hu, B; Hu, Y; Liu, Y; Liu, Z; Su, D; Sun, H; Wang, H; Wang, Z; Xu, X; Zhang, F; Zhang, R; Zhao, C; Zhuo, C | 1 |
| Lee, CH; Lee, LN; Lee, MC; Wang, JT; Wang, JY; Yu, MC | 1 |
| Fujii, T; Ito, A; Nakaminami, H; Noguchi, N; Utsumi, K | 1 |
| Chang, SH; Chien, HI; Chien, ST; Hsu, CH; Hsueh, JC; Lee, PL; Lee, TM; Yang, MC; Yang, TF | 1 |
| Balbuena Segura, AI; Corrales Fernández, MJ; Gea Velázquez de Castro, MT | 1 |
| Chan, S; Coulter, MM; Di Pentima, MC; Hossain, J; Rosé, L | 1 |
| Badal, RE; Cao, B; Chen, S; Chu, Y; Duan, Q; Feng, X; Gui, B; Hu, B; Hu, Z; Huang, W; Kong, H; Liao, K; Luo, Y; Ni, Y; Shao, H; Su, J; Sun, Z; Wang, Y; Wu, A; Xu, Y; Yang, Q; Yu, Y; Zhang, H; Zhang, S | 1 |
| Ariza-Prota, MA; Budiño, T; Casan, P; Fole-Vázquez, D; García-Clemente, M; Pando-Sandoval, A | 1 |
| Cao, Z; Chang, L; Chen, P; Cui, S; Hu, C; Kuang, J; Li, J; Liang, Y; Liu, H; Liu, S; Liu, Y; Lv, X; Lv, Y; Ren, Z; Sun, S; Wang, C; Wang, D; Wang, X; Wu, J; Xiao, Z; Xiu, Q; Yang, H; Zhang, Y; Zhao, L; Zhu, D | 1 |
| Chen, L; Chen, X; Jia, X; Li, N; Liu, W; Sun, H; Tong, H; Xiang, R; Xu, Y; Zhang, F; Zhang, J; Zhao, H | 1 |
| Courter, JD; Girotto, JE; Kazazian, C; Nichols, KR | 1 |
| Frith, JA; Hostoffer, RW; Robertson, LM; Tcheurekdjian, H | 1 |
| Blasi, F; Centanni, S; Clerici, M; Garziano, M; Mantero, M; Trabattoni, D | 1 |
| Bergallo, C; Cooper, CA; Dartois, N; Dukart, G; Gandjini, H; Jasovich, A; Mallick, R; Oliva, ME; Tanaseanu, C; Teglia, O | 1 |
| Bergallo, C; Cooper, A; de Wouters, L; Dukart, G; Jasovich, A; Lentnek, A; Mallick, R; Oliva, ME; Teglia, O; Zlocowski, JC | 1 |
| Castaing, N; Cooper, A; Dartois, N; Gandjini, H | 1 |
| Bongiorno, D; Cafiso, V; Campanile, F; Crapis, M; Cristini, F; Sartor, A; Scarparo, C; Spina, D; Stefani, S; Viale, P | 1 |
| Attridge, RT; Fisher, A; Frei, CR; Jaso, TC; Makos, BR; Mody, SH; Mortensen, EM; Oramasionwu, CU; Raut, MK; Restrepo, MI; Ruiz, AD; Ruiz, JL; Schein, JR | 1 |
| Arija, V; Bejarano-Romero, F; Cliville-Guasch, X; de Diego, C; Gomez-Bertomeu, F; Ochoa-Gondar, O; Raga-Luria, X; Salsench, E; Vila-Corcoles, A | 1 |
| Basuino, L; Chambers, HF; Tattevin, P | 1 |
| Garber, SM; Miller, SM; Pound, MW | 1 |
| Rapp, RP | 1 |
| Calistru, PI; Castaing, N; Chernyak, V; Cooper, CA; Dartois, N; Gandjini, H; Milutinovic, S; Strausz, J; Tanaseanu, C; Zolubas, M | 1 |
| Chang, LY; Hsieh, YC; Hsueh, PR; Huang, LM; Huang, YC; Lin, HC | 1 |
| Cao, GY; Huang, JA; Liu, YB; Shi, YG; Si, B; Sun, SH; Wu, XJ; Xia, QM; Xiao, ZK; Xu, JF; Zhang, J; Zhang, YY | 1 |
| Fisher, AC; Grant, R; Gu, A; Mody, SH; Ng, D; Raut, M; Schein, J; Sengupta, A; Sheng Duh, M; Signorovitch, JE | 1 |
| Carratalà, J; Garcia-Vidal, C | 1 |
| Arnold, F; Griffin, AT; Peyrani, P; Wiemken, T | 1 |
| Baek, YS; Cheong, MH; Durey, A; Lee, JS; Lee, K; Park, JS; Ryu, JS | 1 |
| Blasi, F | 2 |
| Petrosillo, N | 1 |
| Elkhatib, WF; Noreddin, AM | 1 |
| Haftbaradaran, A; Mokabberi, R; Ravakhah, K | 1 |
| Chen, CC; Fisher, AC; Hess, G; Hill, JW; Mody, S; Raut, MK; Schein, JR | 1 |
| Cohen, R; Grimprel, E | 1 |
| Cervera, C; del Río, A; Fernández-Ruiz, M; Marco, F; Miró, JM; Moreno, A; Pérez, G; Pitart, C | 1 |
| Schafer, KR; Wispelwey, B | 1 |
| Rókusz, L | 1 |
| Bajwa, AA; Cury, JD; Samuel, V | 1 |
| Guchev, IA; Iudenich, OV; Melekhina, EV | 1 |
| Chen, WJ; Chuang, CP; Chuang, TY; Hsueh, PR; Jong, YS; Lee, SW; Lin, CJ | 1 |
| Biedenbach, DJ; Farrell, DJ; Flamm, RK; Jones, RN; Liverman, LC; McIntyre, G | 1 |
| Liapikou, A; Torres, A | 1 |
| Chang, JH; Kim, JH; Kim, SW; Lee, JH; Ryu, YJ | 1 |
| Babinchak, T; Cooper, AC; Gardiner, D; Ramirez, JA; Wiemken, T | 1 |
| Carlos, CC; Chung, DR; Hsueh, PR; Kang, CI; Kim, SH; Peck, KR; Perera, J; So, TM; Song, JH; Thamlikitkul, V; Van, PH; Wang, H; Yasin, RM | 1 |
| Chen, PL; Hung, YP; Ko, WC; Wu, YH | 1 |
| Bru, JP | 1 |
| Bahal, N; Frank, E; Freitag, S; Kahn, JB; Kinasewitz, G; Liu, J; Moran, GJ; Olson, WH; Oross, MP; Reichl, V; Tennenberg, A; Wiesinger, BA | 1 |
| Cabré, X; Falguera, M; Ferrer, G; Pérez, J; Ruiz, A; Sacristán, O; Vallverdú, M | 1 |
| Díaz de Tuesta Chow-Quan, AM; Dimas Nuñez, JF; Geijo Martínez, MP; Gómez Criado, C; Herranz, CR; Saiz García, F | 1 |
| Gopal Rao, G; Mahankali Rao, CS; Starke, I | 1 |
| Malcolm, C; Marrie, TJ | 1 |
| Burgmann, H; Kumbein, F; Lukas, A; Mayer, B; Oberbauer, R | 1 |
| Anderson, KB; DiPersio, JR; File, TM; Low, DE; Tan, JS; Willey, BM | 1 |
| Dunbar, LM; Habib, MP; Kahn, JB; Khashab, MM; Smith, LG; Tennenberg, AM; Wiesinger, BA; Wunderink, RG; Xiang, JX; Zadeikis, N | 1 |
| Alfandari, S; d'Escrivan, T; Guery, B; Roussel-Delvallez, M | 1 |
| Alonso-Tarrés, C; Bastida, T; Campos, J; Cortés-Lletget, MC; de la Campa, AG; Pérez-Vázquez, M; Román, F; Tubau, F | 1 |
| Bille, J; Bochud, PY; Calandra, T; Cometta, A; Erard, V; Lamy, O | 1 |
| Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sánchez, M | 2 |
| Dunbar, LM; Kahn, JB; Khashab, MM; Tennenberg, AM; Xiang, JX; Zadeikis, N | 1 |
| Martinez, FJ | 1 |
| Chen, MJ; Hu, BJ; Li, HY; Liu, Y; Sun, ZY; Wang, H; Yu, YS | 1 |
| Greenberg, RN; Khashab, MM; Olson, WH; Stout, JE; Tennenberg, AM; Yu, VL; Zadeikis, N | 1 |
| Marrie, TJ | 1 |
| File, TM | 1 |
| File, TM; Khashab, MM; Milkovich, G; Tennenberg, AM; Xiang, JX; Zadeikis, N | 1 |
| Calandra, T; Cometta, A; Erard, V; Lamy, O; Wasserfallen, JB | 1 |
| Chan, CK; Hoban, DJ; Marras, TK; Noreddin, AM; Sanders, K; Zhanel, GG | 1 |
| Brown, SD; Farrell, DJ; Morrissey, I | 1 |
| Abdulla, RH; Amsden, GW; Andrews, CP; de Caprariis, PJ; Knirsch, CA; Lode, H; Mandell, LA; McIvor, A; Niederman, MS; Vrooman, PS; Zervos, M | 1 |
| González-Granda, D; Labrador, T; Martínez, I; Nieto, A; Querol-Borrás, JM; Querol-Ribelles, JM; Tenías, JM | 1 |
| Ambrose, PG; Bhavnani, SM; Hammel, JP; Jones, RN | 1 |
| Allaouchiche, B; Boselli, E; Breilh, D; Chassard, D; Djabarouti, S; Rimmelé, T; Saux, MC | 1 |
| Carratalà, J; Castellsagué, X; Dorca, J; Fernández-Agüera, A; Fernández-Sabé, N; Gudiol, F; Manresa, F; Martínez, J; Ortega, L; Rosón, B; Verdaguer, R | 1 |
| Dib, C; Durand, C; Moniot-Ville, N; Weber, P | 1 |
| Armstrong, EP; Malone, DC; Ramachandran, S; Skrepnek, GH | 1 |
| Aguado, JM; Carlavilla, AB; Chaves, F; Echave-Sustaeta, J; López-Medrano, F; Villena, V | 1 |
| Arnold, FW; Wojda, B | 1 |
| Bédos, JP; Caulin, E; Leroy, O; Saux, P | 1 |
| Hoban, DJ; Noreddin, AM; Zhanel, GG | 1 |
| Breen, JD; Camere, MA; D'Ignazio, J; Jorgensen, D; Lewis, DE | 1 |
| Shorr, AF; Tennenberg, AM; Wes Ely, E; Xiang, JX; Zadeikis, N | 1 |
| Ivanov, DV; Sidorenko, SV | 1 |
| Harnett, J; Matchar, DB; Samsa, GP; Wilson, J | 1 |
| Anzueto, A; Choudhri, S; Dimarco, JP; Morganroth, J; Niederman, MS | 1 |
| Bettaccini, AA; Brigante, G; Endimiani, A; Grossi, P; Luzzaro, F; Toniolo, AQ | 1 |
| Anzueto, A; Choudhri, SH; Heyder, A; Niederman, MS; Pearle, J; Restrepo, MI | 1 |
| Díaz F, A; Pavié G, J; Prida C, JM; Saldías P, F | 1 |
| Blasi, F; Tarsia, P | 1 |
| Carratalá, J; García-Rey, C; Martín-Herrero, JE; Mykietiuk, A | 1 |
| Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC | 1 |
| Kahn, JB; Khashab, MM; Shorr, AF; Tennenberg, AM; Xiang, JX | 1 |
| Aguilar, L; Alou, L; Cafini, F; Echeverría, O; Giménez, MJ; Pérez-Trallero, E; Prieto, J; Sevillano, D | 1 |
| Sollet, JP | 1 |
| Cantón, R; Graninger, W; Lode, H; Milkovich, G | 1 |
| Concia, E; Marchetti, F | 1 |
| File, TM; Lynch, JP; Zhanel, GG | 1 |
| Chazan, R; Grabczak, M; Karwat, KJ | 1 |
| Armstrong, A; Baqar, S; Bodhidatta, L; Faix, DJ; Fox, A; Hshieh, P; Lawler, JV; Lebron, C; Lewis, M; Maley, EA; Mason, C; Nayak, G; Pang, LW; Pitarangsi, C; Sanders, JW; Scott, DA; Tribble, DR | 1 |
| DeRyke, AC; Fan, HW; Lee, SY; Nicolau, DP; Sutherland, C | 1 |
| Arguedas, A; Blumer, JL; Bradley, JS; Melkote, R; Noel, GJ; Sáez-Llorens, X | 1 |
| Grupper, M; Potasman, I | 1 |
| Anderson, VR; Perry, CM | 1 |
| Benson, CJ; Doshi, D; Grant, R; Riedel, AA; Schein, JR; Sikirica, V; Ye, X; Zarotsky, V | 1 |
| Evers, T; Holman, A; Lloyd, A | 1 |
| Arvis, P; Carlet, J; Choudhri, S; Garau, J; Kureishi, A; Le Berre, MA; Lode, H; Read, RC; Torres, A; Winter, J | 1 |
| Doshi, D; Grant, R; Janagap-Benson, C; Olson, W; Schein, J; Sikirica, V | 1 |
| Ambrose, PG; Nightingale, CH; Owens, RC; Quintiliani, R | 1 |
| Dunbar, L; File, TM; Kohler, R; Kojak, C; Player, R; Rubin, A; Segreti, J; Williams, RR | 1 |
| Berman, AL; Chow, AT; Corrado, M; Dornseif, B; Drusano, GL; Fowler, CL; Natarajan, J; Preston, SL; Reichl, V; Wong, FA | 1 |
| Norrby, SR; Petermann, W; Salewski, E; Vetter, N; Willcox, PA | 1 |
| Ariza, H; Ascoli, M; Casellas, JM; Dolmann, A; Gilardoni, M; Goldberg, M; Ivanovic, S; Montero, JM; Orduna, M; Tome, G | 1 |
| Arancibia, F; Maldonado, A; Torres, A | 1 |
| Redondo Sánchez, J | 1 |
| Léophonte, P; Veyssier, P | 1 |
| Feagan, BG; Lau, CY; Marrie, TJ; Vandervoort, MK; Wheeler, SL; Wong, CJ | 1 |
| Elixhauser, A; Feagan, BG; Halpern, MT; Marrie, TJ; Palmer, CS; Rance, L; Zhan, C | 1 |
| Idrahim, KY; Lima Nicodemo, E; Nicodemo, AC | 1 |
| Hammerschlag, MR; Roblin, PM | 1 |
| Ishii, Y; Miyazaki, S; Okamoto, H; Tateda, K; Yamaguchi, K | 1 |
| Chow, C; Kumarasinghe, G; Tambyah, PA | 1 |
| Feagan, BG; Lau, CY; Marrie, TJ; Wheeler, SL; Wong, CJ | 1 |
| Clark, LC; Davis, CW | 1 |
| Halley, HJ | 1 |
| Shah, PM | 1 |
| Bell, T; Benenson, R; Kellogg, J; Manzella, J; Pellerin, G; Pope, D; Robertson, M | 1 |
| Bagilet, D; Diab, M; Javkin, E; Kalbermatter, V | 1 |
| Scheen, AJ | 1 |
| Dunbar, L; Fogarty, CM; Greenberg, RN; Kojak, CM; Marrie, TJ; Morgan, N; Player, R; Williams, RR | 1 |
| Milkovich, G | 1 |
| Feagan, BG | 1 |
| Carbon, C | 1 |
| Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V | 1 |
| Budanov, SV; Smirnova, LB; Vasil'ev, AN | 1 |
| Ambrose, PG; Nicolau, DP | 1 |
| Bai, Y; Lin, Y; Su, W; Xu, Z | 1 |
| Ackerman, BH; Cawley, MJ; Digwood-Lettieri, S; Guilday, RJ; Haith, LR; Patton, ML; Reilly, KJ | 1 |
| Busman, TA; Dattani, D; Devcich, KJ; Gotfried, MH; Notario, GF; Palmer, RN; Riffer, E | 1 |
21 review(s) available for levofloxacin and Community Acquired Infection
| Article | Year |
|---|---|
Clinical Benefits and Cost-Effectiveness of Moxifloxacin as Initial Treatment for Community-Acquired Pneumonia: A Meta-Analysis and Economic Evaluation.
Topics: Community-Acquired Infections; Cost-Benefit Analysis; Humans; Levofloxacin; Moxifloxacin; Pneumonia | 2021 |
The potential role of nemonoxacin for treatment of common infections.
Topics: Anti-Bacterial Agents; Chlamydia Infections; Clostridium Infections; Community-Acquired Infections; Drug Therapy, Combination; Gonorrhea; Humans; Levofloxacin; Pneumonia, Bacterial; Quinolones; Skin Diseases, Bacterial | 2015 |
An update on Legionella.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; Community-Acquired Infections; Cross Infection; Germany; Humans; Incidence; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Ofloxacin; United States | 2010 |
[Therapeutic experience with levofloxacin in pneumonia and COPD].
Topics: Algorithms; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Cross Infection; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Levofloxacin; Multicenter Studies as Topic; Ofloxacin; Pneumonia, Bacterial; Pulmonary Disease, Chronic Obstructive; Recurrence; Treatment Outcome | 2009 |
Levofloxacin in the treatment of community-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Bacterial; Treatment Outcome | 2010 |
Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Topics: Ambulatory Care; Anti-Bacterial Agents; Aza Compounds; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Humans; Levofloxacin; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumonia, Bacterial; Primary Health Care; Quinolines; Streptococcus pneumoniae | 2010 |
Levofloxacin for the treatment of respiratory tract infections.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cross Infection; Humans; Levofloxacin; Ofloxacin; Respiratory Tract Infections; Treatment Outcome | 2012 |
Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).
Topics: Administration, Oral; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Follow-Up Studies; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Treatment Outcome | 2004 |
New insights in the treatment by levofloxacin.
Topics: Anti-Infective Agents; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fluoroquinolones; Guidelines as Topic; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial | 2004 |
Value of short-course antimicrobial therapy in community-acquired pneumonia.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levofloxacin; Male; Microspheres; Ofloxacin; Pneumonia; Time Factors; Treatment Outcome | 2005 |
Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones.
Topics: Adult; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Levofloxacin; Ofloxacin; Pneumonia, Pneumococcal; Streptococcus pneumoniae | 2006 |
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Microbial; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Assessment; Risk Factors; Treatment Outcome | 2006 |
Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Topics: Anti-Bacterial Agents; Bronchitis, Chronic; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Respiratory Tract Infections; Risk Factors | 2006 |
Levofloxacin for the treatment of community-acquired pneumonia.
Topics: Community-Acquired Infections; Humans; Levofloxacin; Ofloxacin; Pneumonia | 2006 |
Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.
Topics: Animals; Anti-Bacterial Agents; Bacterial Infections; Community-Acquired Infections; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Ofloxacin; Pneumonia | 2008 |
New generations of quinolones: with particular attention to levofloxacin.
Topics: Anti-Infective Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; Ofloxacin; Pneumonia; Quinolones | 1997 |
[Clinical experience of levofloxacin in community acquired pneumonia].
Topics: Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Risk Factors | 1999 |
[Levofloxacin for prevalent infections in primary care medicine].
Topics: Anti-Infective Agents; Bacterial Infections; Community-Acquired Infections; Humans; Levofloxacin; Ofloxacin; Primary Health Care; Respiratory Tract Infections; Urinary Tract Infections | 1999 |
The use of levofloxacin in the treatment of respiratory tract infection.
Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Respiratory Tract Infections; Streptococcus pneumoniae | 2000 |
Optimal treatment strategies for community-acquired pneumonia: high-risk patients (geriatric and with comorbidity).
Topics: Age Factors; Aged; Anti-Infective Agents; Community-Acquired Infections; Comorbidity; Drug Resistance, Microbial; Female; Health Status Indicators; Humans; Levofloxacin; Male; Ofloxacin; Pneumonia; Practice Guidelines as Topic; Risk Factors | 2001 |
[The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
Topics: Acute Disease; Animals; Anti-Infective Agents; Bronchitis; Chronic Disease; Community-Acquired Infections; Humans; Levofloxacin; Maxillary Sinusitis; Ofloxacin; Pneumonia, Bacterial; Respiratory Tract Infections; Urinary Tract Infections | 2001 |
54 trial(s) available for levofloxacin and Community Acquired Infection
| Article | Year |
|---|---|
Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Microbial Viability; Middle Aged; Pneumonia, Bacterial; Quinolones; Safety; Treatment Outcome | 2019 |
Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Asia; Azithromycin; Ceftriaxone; Community-Acquired Infections; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Pneumonia; Prospective Studies; Treatment Outcome | 2018 |
Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; China; Community-Acquired Infections; Double-Blind Method; Drug Combinations; Female; Fluoroquinolones; Humans; Levofloxacin; Lung Diseases; Male; Middle Aged; Pneumonia; Quinolones; Safety; South Africa; Taiwan; Treatment Outcome; Young Adult | 2019 |
Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Community-Acquired Infections; Double-Blind Method; Female; Humans; Levofloxacin; Macrolides; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Treatment Outcome; Triazoles; Young Adult | 2013 |
[Antibiotic therapy regimens for mild community-acquired pneumonia in patients with risk factors for ineffective treatment: clinical and economic comparisons].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Pneumonia; Risk Factors; Severity of Illness Index; Treatment Outcome; Young Adult | 2013 |
Clinical efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole for community-acquired pneumonia with aspiration factors.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Moxifloxacin; Pneumonia; Prospective Studies | 2014 |
A randomized controlled clinical trial of levofloxacin 750 mg versus 500 mg intravenous infusion in the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; China; Community-Acquired Infections; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Pneumonia, Bacterial; Treatment Outcome; Young Adult | 2014 |
A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Haemophilus influenzae; Humans; Levofloxacin; Male; Middle Aged; Mycoplasma pneumoniae; Pneumonia, Bacterial; Quinolones; Streptococcus pneumoniae; Treatment Outcome; Young Adult | 2017 |
Immunomodulatory effects of pidotimod in adults with community-acquired pneumonia undergoing standard antibiotic therapy.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Female; Hospitalization; Humans; Immunity, Innate; Immunologic Factors; Levofloxacin; Male; Middle Aged; Pneumonia; Prospective Studies; Pyrrolidonecarboxylic Acid; Thiazolidines; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gram-Negative Bacterial Infections; Haemophilus Infections; Humans; Levofloxacin; Liver Function Tests; Male; Middle Aged; Minocycline; Ofloxacin; Pneumococcal Infections; Pneumonia, Bacterial; Tigecycline; Treatment Outcome | 2008 |
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Haemophilus influenzae; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Moraxella catarrhalis; Multivariate Analysis; Ofloxacin; Pneumonia, Bacterial; Streptococcus pneumoniae; Tigecycline; Treatment Outcome | 2009 |
Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Humans; International Agencies; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Safety; Tigecycline; Treatment Outcome | 2008 |
Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Minocycline; Nausea; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Severity of Illness Index; Tigecycline; Treatment Outcome; Vomiting; Young Adult | 2009 |
Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchitis, Chronic; China; Community-Acquired Infections; Creatinine; Drug Administration Schedule; Female; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Pneumococcal; Prospective Studies; Recurrence | 2009 |
Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Doxycycline; Drug Costs; Female; Follow-Up Studies; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2010 |
High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies | 2012 |
Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Minocycline; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Tigecycline; Treatment Outcome | 2012 |
A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Azithromycin; Ceftriaxone; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Severity of Illness Index | 2002 |
[Community-acquired pneumonia: usefulness of clinical presentation in the selection of antibiotic treatment].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Community-Acquired Infections; Female; Hospitalization; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Ofloxacin; Penicillins; Pneumonia, Bacterial; Treatment Outcome | 2002 |
[Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Clavulanic Acid; Community-Acquired Infections; Drug Therapy, Combination; Female; Hospitalization; Humans; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2002 |
Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy.
Topics: Aged; Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Clostridioides difficile; Community-Acquired Infections; Diarrhea; Female; Humans; Levofloxacin; Male; Ofloxacin; Prospective Studies; Respiratory Tract Infections | 2003 |
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Double-Blind Method; Female; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Pneumonia; Treatment Outcome | 2003 |
Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hospitalization; Hospitals, Teaching; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pilot Projects; Pneumonia, Bacterial; Probability; Prospective Studies; Risk Assessment; Statistics, Nonparametric; Treatment Outcome | 2004 |
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
Topics: Adult; Anti-Bacterial Agents; Chlamydia Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Double-Blind Method; Drug Administration Schedule; Female; Humans; Legionnaires' Disease; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Pneumonia, Mycoplasma | 2004 |
Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Azithromycin; Cefuroxime; Community-Acquired Infections; Critical Pathways; Drug Therapy, Combination; Female; Humans; Levofloxacin; Longitudinal Studies; Male; Middle Aged; Ofloxacin; Oxygen Inhalation Therapy; Pneumococcal Infections; Pneumonia; Pneumonia, Bacterial; Treatment Outcome | 2004 |
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Drug Administration Schedule; Drug Costs; Female; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Treatment Outcome | 2004 |
Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2004 |
Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Azithromycin; Canada; Ceftriaxone; Community-Acquired Infections; Drug Administration Schedule; Female; Germany; Humans; Infusions, Intravenous; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Severity of Illness Index; Treatment Outcome; United States | 2004 |
Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Topics: Aged; Anti-Bacterial Agents; Ceftriaxone; Clarithromycin; Cohort Studies; Community-Acquired Infections; Drug Therapy, Combination; Female; Hospitalization; Humans; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2005 |
Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia.
Topics: Aged; Anti-Bacterial Agents; Capillary Permeability; Community-Acquired Infections; Creatinine; Critical Care; Diffusion; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Hospital Mortality; Humans; Infusions, Intravenous; Levofloxacin; Lung; Male; Metabolic Clearance Rate; Middle Aged; Ofloxacin; Pneumonia, Bacterial | 2005 |
Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Community-Acquired Infections; Female; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Outcome Assessment, Health Care; Patient Satisfaction; Pneumonia, Bacterial; Quality of Life; Risk Factors | 2005 |
Levofloxacin in the treatment of pneumonia in intensive care unit patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Critical Illness; Cross Infection; Drug Administration Schedule; Female; Humans; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Treatment Outcome | 2004 |
Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefotaxime; Chi-Square Distribution; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Treatment Outcome | 2005 |
Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Chemistry, Pharmaceutical; Community-Acquired Infections; Double-Blind Method; Female; Humans; Incidence; Levofloxacin; Male; Microspheres; Middle Aged; Ofloxacin; Outpatients; Pneumonia; Serologic Tests; Time Factors; Treatment Outcome | 2005 |
A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Double-Blind Method; Drug Administration Schedule; Female; Humans; Levofloxacin; Male; Multicenter Studies as Topic; Ofloxacin; Pneumonia; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2005 |
A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired Infections; Costs and Cost Analysis; Drug Therapy, Combination; Female; Home Care Services; Hospitalization; Humans; Length of Stay; Levofloxacin; Male; Ofloxacin; Pneumonia, Bacterial; United States | 2005 |
A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Double-Blind Method; Electrocardiography, Ambulatory; Female; Fluoroquinolones; Heart Conduction System; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines | 2005 |
Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Safety | 2006 |
Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Community-Acquired Infections; Drug Administration Schedule; Hospitalization; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Severity of Illness Index; Streptococcus pneumoniae; Treatment Outcome | 2006 |
Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Community-Acquired Infections; Drug Administration Schedule; Female; Hospitalization; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Ofloxacin; Patient Discharge; Penicillanic Acid; Pilot Projects; Piperacillin; Piperacillin, Tazobactam Drug Combination; Urinary Tract Infections | 2006 |
Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Campylobacter Infections; Campylobacter jejuni; Community-Acquired Infections; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Bacterial; Dysentery; Escherichia coli Infections; Female; Humans; Levofloxacin; Male; Military Personnel; Ofloxacin; Salmonella Infections; Thailand | 2007 |
Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Topics: Adolescent; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ceftriaxone; Child; Child, Preschool; Clarithromycin; Community-Acquired Infections; Drug Therapy, Combination; Erythromycin; Female; Humans; Infant; Infant, Newborn; Levofloxacin; Male; Ofloxacin; Pneumonia; Treatment Outcome | 2007 |
A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Topics: Administration, Oral; Aza Compounds; Ceftriaxone; Community-Acquired Infections; Cost of Illness; Cost-Benefit Analysis; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Hospitalization; Humans; Infusions, Intravenous; Length of Stay; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Ceftriaxone; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Quinolines; Severity of Illness Index; Treatment Outcome | 2008 |
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prodrugs; Prospective Studies; Treatment Outcome | 1997 |
A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Hospitalization; Humans; International Cooperation; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Treatment Outcome | 1998 |
[Levofloxacin in the treatment of community-acquired pneumococcal pneumonia].
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Clavulanic Acid; Community-Acquired Infections; Drug Therapy, Combination; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pneumonia, Pneumococcal | 1999 |
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Topics: Aged; Anti-Infective Agents; Canada; Community-Acquired Infections; Critical Pathways; Female; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Outcome Assessment, Health Care; Pneumonia; Sickness Impact Profile; Statistics, Nonparametric | 2000 |
Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.
Topics: Aged; Anti-Infective Agents; Canada; Cluster Analysis; Community-Acquired Infections; Critical Pathways; Delivery of Health Care; Female; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Severity of Illness Index | 2000 |
Predictors of symptom resolution in patients with community-acquired pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Gastrointestinal Diseases; Humans; Levofloxacin; Male; Middle Aged; Multivariate Analysis; Ofloxacin; Pneumonia, Bacterial; Predictive Value of Tests; Treatment Outcome | 2000 |
[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization].
Topics: Administration, Oral; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Analysis of Variance; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Prospective Studies | 2000 |
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Erythromycin; Humans; Levofloxacin; Ofloxacin; Pneumonia, Pneumococcal | 2001 |
A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Canada; Community-Acquired Infections; Critical Pathways; Hospitalization; Humans; Injections, Intravenous; Length of Stay; Levofloxacin; Ofloxacin; Pneumonia; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2001 |
A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Treatment Outcome | 2002 |
100 other study(ies) available for levofloxacin and Community Acquired Infection
| Article | Year |
|---|---|
Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Genes, Bacterial; Hospitals; Humans; Korea; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Molecular Epidemiology; Mutation; Ofloxacin; Pneumococcal Infections; Polymerase Chain Reaction; Prevalence; Reserpine; Respiratory Tract Infections; Retrospective Studies; Streptococcus pneumoniae | 2007 |
Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Fluoroquinolones; Hospitalization; Humans; Length of Stay; Macrolides; Male; Middle Aged; New York; Pneumonia, Bacterial; Retrospective Studies; Treatment Outcome; Veterans | 2007 |
National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study.
Topics: Anti-Bacterial Agents; Azithromycin; Bacterial Infections; beta-Lactams; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Geography; Haemophilus influenzae; Health Surveys; Humans; Moraxella catarrhalis; Penicillin Resistance; Respiratory Tract Infections; Streptococcus pneumoniae; Trimethoprim, Sulfamethoxazole Drug Combination; United States | 2007 |
Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Infant; Infant, Newborn; Macrolides; Microbial Sensitivity Tests; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; RNA, Ribosomal, 23S | 2008 |
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbapenems; Ceftaroline; Cephalosporins; Community-Acquired Infections; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus; United States | 2008 |
In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.
Topics: Anti-Infective Agents; Bacteria; Community-Acquired Infections; Cross Infection; Enterococcus; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Structure; Oxazolidinones; Respiratory System; Staphylococcus; Staphylococcus aureus; Streptococcus; Streptococcus pneumoniae | 2008 |
Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.
Topics: Animals; Anti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Cross Infection; Disease Models, Animal; Drug Resistance, Bacterial; Female; Humans; Methicillin Resistance; Mice; Mice, Inbred BALB C; Phenotype; Pneumonia, Staphylococcal; Staphylococcus aureus | 2008 |
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Pneumonia; Quinolones; Randomized Controlled Trials as Topic; Tuberculosis, Pulmonary | 2022 |
Risk factor-based analysis of community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia: Microbiological distribution, antibiotic resistance, and clinical outcomes.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cross Infection; Drug Resistance, Microbial; Healthcare-Associated Pneumonia; Hospitals; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Pneumonia; Pseudomonas aeruginosa; Retrospective Studies; Risk Factors | 2022 |
Clinical Benefit of Empiric High-Dose Levofloxacin Therapy for Adults With Community-onset Enterobacteriaceae Bacteremia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Cohort Studies; Community-Acquired Infections; Comorbidity; Enterobacteriaceae Infections; Female; Humans; Length of Stay; Levofloxacin; Male; Neoplasms; Retrospective Studies | 2019 |
Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Pneumonia; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2018 |
Acute fibrinous and organising pneumonia.
Topics: Anti-Bacterial Agents; Biopsy; Community-Acquired Infections; Cryptogenic Organizing Pneumonia; Diagnosis, Differential; Female; Fever; Fibrin; Glucocorticoids; Humans; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Lung; Lung Diseases, Interstitial; Middle Aged; Pneumonia; Prednisolone; Radiography; Rare Diseases; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Age-Related Trends in Adults with Community-Onset Bacteremia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Community-Acquired Infections; Escherichia coli; Female; Humans; Klebsiella pneumoniae; Levofloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Proteus mirabilis; Retrospective Studies; Young Adult | 2017 |
Initial empiric antibiotic therapy for community-acquired pneumonia in Chinese hospitals.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; China; Community-Acquired Infections; Female; Fluoroquinolones; Hospital Mortality; Hospitalization; Humans; Length of Stay; Levofloxacin; Logistic Models; Male; Middle Aged; Pneumonia; Sex Factors; Treatment Failure; Young Adult | 2018 |
Risk Factors for Community-Onset Pneumonia Caused by Levofloxacin-Nonsusceptible Streptococcus pneumoniae.
Topics: Aged; Anti-Bacterial Agents; Case-Control Studies; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Pneumonia, Pneumococcal; Retrospective Studies; Risk Factors; Streptococcus pneumoniae | 2018 |
Leave the levofloxacin? A case report of levofloxacin-induced psychosis.
Topics: Aged; Anti-Infective Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Pneumonia; Psychoses, Substance-Induced | 2018 |
Impact of an antimicrobial stewardship program on outcomes in patients with community-acquired pneumonia admitted to a tertiary community hospital.
Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Azithromycin; Ceftriaxone; Community-Acquired Infections; Female; Hospitals, Community; Humans; Length of Stay; Levofloxacin; Male; Pneumonia, Bacterial; Retrospective Studies; Tertiary Care Centers; Treatment Outcome | 2018 |
Drug induced thrombotic microangiopathy caused by levofloxacin.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Humans; Legionnaires' Disease; Levofloxacin; Male; Middle Aged; Thrombotic Microangiopathies | 2018 |
Community Acquired Legionnaire's Disease in a Kidney Transplant Patient.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Critical Care; Humans; Immunocompromised Host; Kidney Transplantation; Legionellosis; Legionnaires' Disease; Levofloxacin; Male; Middle Aged; Piperacillin, Tazobactam Drug Combination; Pneumonia; Radiography, Thoracic; Treatment Outcome | 2018 |
Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; beta-Lactams; Community-Acquired Infections; Drug Therapy, Combination; Female; Hospital Mortality; Hospitalization; Humans; Japan; Levofloxacin; Male; Middle Aged; Pneumonia, Bacterial; Severity of Illness Index; Treatment Outcome | 2019 |
Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactam Resistance; Case-Control Studies; Community-Acquired Infections; Female; Hong Kong; Humans; Korea; Levofloxacin; Male; Middle Aged; Pneumonia, Pneumococcal; Prospective Studies; Risk Factors; Streptococcus pneumoniae; Taiwan; Young Adult | 2014 |
Fever of unknown origin in a young man.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Community-Acquired Infections; Fever; Fever of Unknown Origin; Gram-Negative Bacterial Infections; Humans; Immunocompromised Host; Levofloxacin; Male; Sphingomonas | 2014 |
A novel cause of community-acquired pneumonia in a young immunocompetent host.
Topics: Actinomycetales Infections; Adult; Bronchoalveolar Lavage Fluid; Community-Acquired Infections; Diagnosis, Differential; Gordonia Bacterium; Humans; Immunocompetence; Levofloxacin; Male; Pneumonia; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Comparison of the effectiveness and antibiotic cost among ceftriaxone, ertapenem, and levofloxacin in treatment of community-acquired complicated urinary tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Costs and Cost Analysis; Ertapenem; Escherichia coli; Female; Humans; Length of Stay; Levofloxacin; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Tract Infections; Young Adult | 2016 |
[Resistance surveillance of major pathogens for adult community-acquired respiratory tract infections in China: a multicenter study 2012].
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Cephalosporins; China; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Haemophilus influenzae; Humans; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillins; Respiratory Tract Infections; Streptococcus pneumoniae | 2015 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Linear Models; Longitudinal Studies; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Taiwan; Tuberculosis, Pulmonary; Young Adult | 2015 |
Increase in SCCmec type IV strains affects trends in antibiograms of meticillin-resistant Staphylococcus aureus at a tertiary-care hospital.
Topics: Bacterial Toxins; Bacterial Typing Techniques; Cefotaxime; Chromosomes, Bacterial; Clarithromycin; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterotoxins; Exotoxins; Humans; Interspersed Repetitive Sequences; Japan; Leukocidins; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Minocycline; Staphylococcal Infections; Superantigens; Tertiary Care Centers; Virulence Factors | 2015 |
Molecular Characterization of Community- and Healthcare-Associated Methicillin-Resistant Staphylococcus aureus Isolates in Southern Taiwan.
Topics: Anti-Bacterial Agents; Bacterial Typing Techniques; Base Sequence; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gene Expression Regulation, Bacterial; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Moxifloxacin; Staphylococcal Infections; Taiwan | 2015 |
[Skin infection by community-acquired methicillin resistant Staphylococcus aureus with familial transmission].
Topics: Abscess; Adolescent; Adult; Anti-Bacterial Agents; Carrier State; Child; Community-Acquired Infections; Drug Therapy, Combination; Emergencies; Family Health; Humans; Levofloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Parents; Siblings; Staphylococcal Skin Infections; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin | 2016 |
Trends of fluoroquinolone-resistant Escherichia coli amongst urinary isolates in children: a 10 year surveillance study.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Bacterial; Epidemiological Monitoring; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Infant; Infant, Newborn; Levofloxacin; Male; Microbial Sensitivity Tests; Urinary Tract Infections | 2015 |
Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; China; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Gene Expression; Humans; Imipenem; Intraabdominal Infections; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2016 |
Community-acquired bacteremic Streptomyces atratus pneumonia in animmunocompetent adult: a case report.
Topics: Actinomycetales Infections; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Bronchoscopy; Community-Acquired Infections; Humans; Imipenem; Immunocompetence; Levofloxacin; Male; Pneumonia, Bacterial; Sequence Analysis, DNA; Streptomyces; Treatment Outcome | 2015 |
[Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014].
Topics: Anti-Bacterial Agents; Aza Compounds; Cefepime; Cephalosporins; China; Clarithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Klebsiella pneumoniae; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillins; Respiratory Tract Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2016 |
Pharmacodynamically Guided Levofloxacin Dosing for Pediatric Community-Acquired Pneumonia.
Topics: Adolescent; Age Factors; Anti-Bacterial Agents; Child; Child, Preschool; Community-Acquired Infections; Dose-Response Relationship, Drug; Humans; Infant; Levofloxacin; Microbial Sensitivity Tests; Monte Carlo Method; Pneumonia, Pneumococcal; Streptococcus pneumoniae | 2017 |
Possible mast cell activation syndrome in a patient undergoing long-term hemodialysis.
Topics: Aged; Amlodipine; Anaphylaxis; Carbazoles; Carvedilol; Community-Acquired Infections; Deglutition Disorders; Epinephrine; Female; Humans; Kidney Failure, Chronic; Levofloxacin; Mastocytosis; Pneumonia; Propanolamines; Renal Dialysis; Tryptases | 2016 |
Pathotype and susceptibility profile of a community-acquired methicillin-resistant Staphylococcus aureus strain responsible for a case of severe pneumonia.
Topics: Adult; Bacterial Proteins; Bacterial Toxins; Community-Acquired Infections; DNA Primers; Exotoxins; Humans; Italy; Leukocidins; Levofloxacin; Male; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Staphylococcal; Polymerase Chain Reaction; Serotyping | 2009 |
Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
Topics: Adult; Aged; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Community-Acquired Infections; Drug Therapy, Combination; Female; Health Resources; Humans; Least-Squares Analysis; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Practice Guidelines as Topic; Societies, Medical; United States | 2009 |
Drug-resistance in Streptococcus pneumoniae isolates among Spanish middle aged and older adults with community-acquired pneumonia.
Topics: Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Blood; Cefotaxime; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Erythromycin; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Oxacillin; Pneumococcal Infections; Serotyping; Spain; Sputum; Streptococcus pneumoniae | 2009 |
Subinhibitory fluoroquinolone exposure selects for reduced beta-lactam susceptibility in methicillin-resistant Staphylococcus aureus and alterations in the SOS-mediated response.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactams; Ciprofloxacin; Community-Acquired Infections; DNA Gyrase; DNA Mutational Analysis; DNA Transposable Elements; Fluoroquinolones; Gene Expression Profiling; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Nafcillin; Ofloxacin; Penicillin-Binding Proteins; Selection, Genetic; SOS Response, Genetics; Staphylococcal Infections; Transcription Factors; Up-Regulation | 2009 |
Hypoglycemia associated with the use of levofloxacin.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Diabetes Mellitus, Type 2; Drug Interactions; Glipizide; Humans; Hypoglycemia; Hypoglycemic Agents; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia | 2009 |
Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Azithromycin; Community-Acquired Infections; Doxycycline; Drug Resistance, Multiple, Bacterial; Humans; Kentucky; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Respiratory Tract Infections; Streptococcus pneumoniae; Treatment Outcome; United States | 2002 |
Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Anti-Bacterial Agents; Base Sequence; Child; Child, Preschool; Community-Acquired Infections; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Molecular Epidemiology; Ofloxacin; Pneumococcal Infections; Pneumonia, Pneumococcal; Polymerase Chain Reaction; Risk Factors; Sequence Analysis, Protein; Serotyping; Streptococcus pneumoniae; Taiwan; Young Adult | 2010 |
Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Ambulatory Care; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Costs and Cost Analysis; Female; Fluoroquinolones; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Outpatients; Pneumonia; Quinolines; Young Adult | 2010 |
Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Topics: Administration, Oral; Anti-Bacterial Agents; Azithromycin; Chi-Square Distribution; Clarithromycin; Community-Acquired Infections; Female; Humans; Kaplan-Meier Estimate; Legionella pneumophila; Legionnaires' Disease; Length of Stay; Levofloxacin; Male; Ofloxacin; Retrospective Studies; Time Factors; Treatment Outcome | 2010 |
Levofloxacin-induced Achilles tendinitis in a young adult in the absence of predisposing conditions.
Topics: Achilles Tendon; Adult; Anti-Bacterial Agents; Community-Acquired Infections; Disease Susceptibility; Humans; Levofloxacin; Male; Ofloxacin; Pneumonia; Tendinopathy; Young Adult | 2010 |
[Experience accumulated in hospital setting with levofloxacin, in monotherapy and in association therapy].
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Hospital Departments; Humans; Levofloxacin; Multicenter Studies as Topic; Neoplasms; Neutropenia; Ofloxacin; Practice Guidelines as Topic; Risk Factors; Treatment Outcome | 2009 |
Comparative antibiotic failure rates in the treatment of community-acquired pneumonia: Results from a claims analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Community-Acquired Infections; Female; Humans; Insurance Claim Review; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Factors; Treatment Failure | 2010 |
[Levofloxacin in children].
Topics: Adult; Anti-Bacterial Agents; Bacterial Infections; Child; Community-Acquired Infections; Humans; Levofloxacin; Mycoplasma pneumoniae; Ofloxacin; Otitis Media; Pneumococcal Infections; Pneumonia; Sinusitis; Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
Community-acquired methicillin-resistant Staphylococcus aureus meningitis complicated by cerebral infarction. Role of antibiotic combination of linezolid plus levofloxacin.
Topics: Acetamides; Adult; Anti-Bacterial Agents; Cerebral Infarction; Community-Acquired Infections; Drug Therapy, Combination; Humans; Levofloxacin; Linezolid; Male; Meningitis, Bacterial; Methicillin-Resistant Staphylococcus aureus; Ofloxacin; Oxazolidinones; Staphylococcal Infections | 2010 |
Case of Legionella pneumonia complicated with pulmonary thromboembolism.
Topics: Anti-Bacterial Agents; Anticoagulants; Community-Acquired Infections; Heparin; Humans; Legionnaires' Disease; Levofloxacin; Male; Middle Aged; Ofloxacin; Pulmonary Embolism; Thrombophilia | 2010 |
First case of Legionella pneumophila native valve endocarditis.
Topics: Adult; Aortic Valve; Community-Acquired Infections; Endocarditis, Bacterial; Female; Humans; Immunosuppression Therapy; Legionella pneumophila; Levofloxacin; Ofloxacin; Rifampin | 2011 |
[Levofloxacin. expediency of high-dose regimens in therapy of lower respiratory tract infections].
Topics: Community-Acquired Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Ofloxacin; Pneumonia; Pulmonary Disease, Chronic Obstructive | 2011 |
Rapidly fatal community-acquired pneumonia due to Klebsiella pneumoniae complicated with acute myocarditis and accelerated idioventricular rhythm.
Topics: Accelerated Idioventricular Rhythm; Acidosis, Lactic; Acute Disease; Community-Acquired Infections; Electrocardiography; Fatal Outcome; Humans; Intensive Care Units; Klebsiella pneumoniae; Levofloxacin; Male; Middle Aged; Myocarditis; Ofloxacin; Pneumonia, Bacterial; Shock, Septic | 2012 |
Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Geography; Haemophilus influenzae; Humans; Inhibitory Concentration 50; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Streptococcus pneumoniae | 2012 |
Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumococcal Infections; Population Surveillance; Prospective Studies; Risk Factors; Streptococcus pneumoniae; Treatment Outcome | 2013 |
Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Cefazolin; Community-Acquired Infections; Comorbidity; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Prospective Studies; Risk Factors; Taiwan; Urinary Tract Infections; Young Adult | 2014 |
[Update on the role of levofloxacin in the management of acute community-acquired pneumonia].
Topics: Acute Disease; Anti-Infective Agents; Bacteremia; Community-Acquired Infections; Humans; Levofloxacin; Ofloxacin; Pneumonia; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
Topics: Adolescent; Adult; Aged; Alberta; Ambulatory Care; Analysis of Variance; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Emergency Service, Hospital; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2003 |
The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Child; Child, Preschool; Chlamydophila Infections; Chlamydophila pneumoniae; Cluster Analysis; Cohort Studies; Community-Acquired Infections; Comorbidity; Female; Haemophilus Infections; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Respiratory Tract Infections; Treatment Outcome | 2003 |
Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Humans; Immunocompromised Host; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Pneumococcal Infections; Pneumonia, Pneumococcal; Streptococcus pneumoniae | 2003 |
High level of resistance to levofloxacin of Streptococcus pneumoniae following fluoroquinolone therapy.
Topics: Aged; Cefotaxime; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Follow-Up Studies; Humans; Infusions, Intravenous; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Pneumococcal; Risk Assessment; Severity of Illness Index; Streptococcus pneumoniae; Treatment Outcome | 2003 |
Levofloxacin treatment failure in Haemophilus influenzae pneumonia.
Topics: Aged; Anti-Infective Agents; Community-Acquired Infections; DNA Gyrase; Electrophoresis, Gel, Pulsed-Field; Fatal Outcome; Female; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Molecular Sequence Data; Ofloxacin; Pneumonia; Treatment Failure | 2003 |
[Observational study investigating the use of levofloxacin in ICU patients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Arrhythmias, Cardiac; Bacterial Infections; Chemical and Drug Induced Liver Injury; Community-Acquired Infections; Comorbidity; Critical Care; Cross Infection; Diarrhea; Drug Resistance; Drug Therapy, Combination; Drug Utilization; Female; Humans; Infusions, Parenteral; Intensive Care Units; Levofloxacin; Male; Middle Aged; Ofloxacin; Prospective Studies; Respiration, Artificial; Respiratory Tract Infections; Spain | 2004 |
Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
Topics: Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Doxycycline; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitalization; Humans; Levofloxacin; Macrolides; Moxifloxacin; Naphthyridines; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial; Quinolines; Retrospective Studies | 2004 |
[Resistance surveillance of common community respiratory pathogens isolated in China, 2002 - 2003].
Topics: Anti-Bacterial Agents; Cefprozil; Cephalosporins; Child, Preschool; China; Community-Acquired Infections; Drug Resistance, Bacterial; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Multicenter Studies as Topic; Ofloxacin; Penicillins; Respiratory Tract Infections; Streptococcus pneumoniae | 2004 |
Levofloxacin efficacy in the treatment of community-acquired legionellosis.
Topics: Clinical Trials as Topic; Community-Acquired Infections; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Legionella pneumophila; Legionnaires' Disease; Levofloxacin; Male; Ofloxacin; Risk Assessment; Treatment Outcome | 2004 |
Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
Topics: Adolescent; Adult; Aged; Area Under Curve; Community-Acquired Infections; Drug Administration Routes; Female; Hospitalization; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Ofloxacin; Streptococcus pneumoniae | 2004 |
Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Community-Acquired Infections; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Humans; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Ofloxacin; Pneumococcal Infections; Population Surveillance; Prevalence; Respiratory Tract Infections; Streptococcus pneumoniae; United States | 2004 |
Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumococcal Infections; Streptococcus pneumoniae | 2005 |
[Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community].
Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Community-Acquired Infections; Escherichia coli; Escherichia coli Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Staphylococcus aureus; Urinary Tract Infections | 2005 |
An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Community-Acquired Infections; Databases as Topic; Erythromycin; Female; Health Care Costs; Humans; Levofloxacin; Male; Managed Care Programs; Middle Aged; Models, Econometric; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Treatment Outcome | 2005 |
[Failure of levofloxacin therapy in two cases of community-acquired pneumonia caused by fluoroquinolone-resistant Streptococcus pneumoniae and complicated with empyema].
Topics: Aged; Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pneumonia, Pneumococcal; Streptococcus pneumoniae | 2005 |
An analysis of a community-acquired pathogen in a Kentucky community: methicillin-resistant Staphylococcus aureus.
Topics: Adult; Anti-Bacterial Agents; Cefazolin; Clindamycin; Community-Acquired Infections; Erythromycin; Female; Humans; Kentucky; Levofloxacin; Male; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Oxacillin; Rifampin; Risk Factors; Staphylococcal Infections; Staphylococcus aureus; Sulfamethoxazole; Tetracycline; Trimethoprim; Vancomycin | 2005 |
Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; beta-Lactams; Community-Acquired Infections; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pneumonia, Pneumococcal; Polymerase Chain Reaction; Respiratory Tract Infections; Streptococcus pneumoniae | 2005 |
Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
Topics: Adult; Aged; Community-Acquired Infections; Drug Administration Schedule; Epidemiologic Methods; Fluoroquinolones; Gatifloxacin; Hospitalization; Humans; Levofloxacin; Middle Aged; Monte Carlo Method; Ofloxacin; Pneumococcal Infections; Predictive Value of Tests; Streptococcus pneumoniae | 2005 |
[Results of the study on antibiotic resistance emergence among pathogens of community-acquired urinary tract infections in Moscow. Phase I].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Bacterial Infections; Cephalosporins; Community-Acquired Infections; Drug Resistance; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Levofloxacin; Male; Middle Aged; Moscow; Ofloxacin; Urinary Tract Infections | 2005 |
Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; Community-Acquired Infections; DNA Topoisomerases, Type II; Drug Resistance, Multiple, Bacterial; Humans; Levofloxacin; Ofloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Pneumococcal; Streptococcus pneumoniae; Streptolysins; Treatment Failure | 2005 |
[Assessment of the management of community-acquired pneumonia in adults outpatients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Amoxicillin; Anti-Bacterial Agents; Chi-Square Distribution; Clarithromycin; Community-Acquired Infections; Emergencies; Female; Frail Elderly; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Prospective Studies; Treatment Failure | 2005 |
A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Serum Bactericidal Test; Streptococcus pneumoniae | 2006 |
Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Humans; Levofloxacin; Ofloxacin; Respiratory Tract Infections; Risk Factors | 2006 |
[Efficacy and safety of levofloxacin treatment of community--acquired pneumonia in hospitalized patients].
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Hospitalization; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Radiography; Treatment Outcome | 2006 |
Antibacterial effects of moxifloxacin and levofloxacin simulating epithelial lining fluid concentrations against community-acquired methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Culture Media; Epithelium; Fluoroquinolones; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2007 |
Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case.
Topics: Adult; Anti-Bacterial Agents; Community-Acquired Infections; Fluoroquinolones; Humans; Levofloxacin; Male; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Radiography; Tuberculosis, Pulmonary | 2008 |
Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Community-Acquired Infections; Cost-Benefit Analysis; Databases as Topic; Drug Costs; Drug Utilization; Emergency Service, Hospital; Female; Health Care Costs; Health Resources; Hospital Costs; Humans; Insurance Claim Reporting; Levofloxacin; Logistic Models; Macrolides; Male; Managed Care Programs; Middle Aged; Odds Ratio; Ofloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Failure | 2008 |
A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Community-Acquired Infections; Comorbidity; Female; Fluoroquinolones; Health Care Costs; Hospitalization; Humans; Infusions, Intravenous; Insurance Claim Review; Length of Stay; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Pneumonia, Bacterial; Quinolines; Research Design; Retrospective Studies; Treatment Outcome; United States | 2008 |
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
Topics: Adult; Anti-Infective Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Ofloxacin | 1998 |
Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bacteria; Bronchitis; Chronic Disease; Community-Acquired Infections; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Middle Aged; Moraxella catarrhalis; Ofloxacin; Penicillin Resistance; Pneumonia, Bacterial; Pseudomonas aeruginosa; Streptococcus pneumoniae | 1999 |
Oral levofloxacin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial | 2000 |
Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Topics: Anti-Infective Agents; Chlamydia Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Outcome Assessment, Health Care; Pneumonia, Bacterial | 2000 |
Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.
Topics: Amoxicillin; Anti-Bacterial Agents; Cefdinir; Cephalosporins; Community-Acquired Infections; Drug Resistance, Microbial; Erythromycin; Gram-Positive Bacteria; Humans; Japan; Ketolides; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Respiratory Tract Infections; Staphylococcus aureus | 2000 |
The emergence of resistance to levofloxacin before clinical use in a university hospital in Singapore.
Topics: Anti-Infective Agents; Community-Acquired Infections; Drug Resistance, Microbial; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Streptococcus pneumoniae | 2000 |
Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Community-Acquired Infections; Costs and Cost Analysis; Diagnosis-Related Groups; Drug Costs; Female; Hospitalization; Humans; Injections, Intravenous; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Ofloxacin; Pneumonia; Practice Guidelines as Topic; Retrospective Studies; Treatment Outcome | 2000 |
Approaches to drug therapy, formulary, and pathway management in a large community hospital.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Community-Acquired Infections; Cost-Benefit Analysis; Critical Pathways; Disease Management; Drug Costs; Drug Therapy, Computer-Assisted; Formularies, Hospital as Topic; Hospitals, Community; Humans; Indiana; Injections, Intravenous; Length of Stay; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pharmacy Service, Hospital; Pneumonia; Seasons; Treatment Outcome | 2000 |
Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Drug Therapy, Combination; Enterococcus; Erythromycin; Female; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Prospective Studies; Risk Factors; Vancomycin Resistance | 2000 |
[Pharma-clinics. The drug of the month. Levofloxacin (Tavanic)].
Topics: Acute Disease; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacterial Infections; Bronchitis; Community-Acquired Infections; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial; Sinusitis; Urinary Tract Infections | 2000 |
Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.
Topics: Administration, Oral; Aged; Anti-Infective Agents; APACHE; Ciprofloxacin; Community-Acquired Infections; Cost-Benefit Analysis; Drug Utilization; Female; Hospitalization; Humans; Injections, Intravenous; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia; Virginia | 2001 |
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 2001 |
Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae.
Topics: Adolescent; Adult; Anti-Infective Agents; Area Under Curve; Community-Acquired Infections; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Models, Statistical; Monte Carlo Method; Ofloxacin; Predictive Value of Tests; Streptococcus pneumoniae | 2001 |
Clinical effects and bronchoalveolar transfer of levofloxacin in patients with community-acquired pneumonia.
Topics: Adult; Aged; Anti-Infective Agents; Bacteria; Bronchoalveolar Lavage Fluid; Community-Acquired Infections; Female; Humans; Levofloxacin; Male; Middle Aged; Ofloxacin; Pneumonia, Bacterial; Time Factors; Treatment Outcome | 2001 |
Levofloxacin-induced toxic epidermal necrolysis in an elderly patient.
Topics: Aged; Anti-Infective Agents; Community-Acquired Infections; Female; Fluid Therapy; Humans; Levofloxacin; Ofloxacin; Pneumonia; Pulmonary Disease, Chronic Obstructive; Skin; Stevens-Johnson Syndrome | 2002 |